The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms.

Borbath, Ivan; Garcia-Carbonero, Rocio; Bikmukhametov, Damir; Jimenez-Fonseca, Paula; Castaño, Angel; Barkmanova, Jaroslava; Sedlackova, Eva; Kollár, Attila; Christ, Emanuel; Kaltsas, Gregory; Kos-Kudla, Beata; Maasberg, Sebastian; Verslype, Chris; Pape, Ulrich-Frank (2022). The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms. European journal of cancer, 168, pp. 80-90. Elsevier 10.1016/j.ejca.2022.03.007

[img] Text
1-s2.0-S0959804922001472-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

BACKGROUND

Neuroendocrine neoplasms (NENs) are rare tumours with variable clinical behaviour. Their natural history is ideally best approached in large, multicentre and multinational registries with long-term patients' follow-up. The European Neuroendocrine Tumour Society registry aims to obtain information regarding NEN outcomes and prognostic factors in a European frame.

PATIENTS AND METHODS

We collected data from 7 national NEN registries (Belgium, Czech Republic, Germany, Greece, Poland, Spain, Switzerland), representing 10,102 patients. Anonymised/pseudonymised data were collected in a secured server. Descriptive statistical methods were applied, as well as Kaplan-Meier survival curves and multivariable analyses for prognostic factors of overall survival (OS).

RESULTS

median age of the study population was 60 years (range: 18-102), 48% were female. Common primary tumour sites were pancreas (27%) and small intestine (21%). Stage 4 disease was found in 47% of patients, while 26/10/16% had stage 1/2/3 disease, respectively. Grading (n = 6952) was G1/2/3 in 48/37/15% of the patients, respectively. Surgery was the main treatment, provided to 71% of patients, followed by somatostatin analogues (32%), chemotherapy (20%), Peptide receptor Radionuclide Therapy (PRRT) (9%) and targeted therapies (8%). OS at 5 years was 74%, influenced by grade, stage and tissue of origin in multivariate analysis. A Ki67 cut-off value set at 55% within the G3 group allowed to separate 2 groups with a meaningful different OS.

CONCLUSION

We report the first analysis of the European Neuroendocrine Tumour Society registry, comprising 10,102 patients with NEN from 7 European countries. This large cohort study describes prognostic factors for the survival of NENs throughout Europe, including primary tumour site, grade, stage and treatment.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Kollár, Attila

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0959-8049

Publisher:

Elsevier

Language:

English

Submitter:

Pubmed Import

Date Deposited:

27 Apr 2022 10:13

Last Modified:

05 Dec 2022 16:19

Publisher DOI:

10.1016/j.ejca.2022.03.007

PubMed ID:

35472579

Uncontrolled Keywords:

Neuroendocrine neoplasms Prognosis Registry Survival Treatment

BORIS DOI:

10.48350/169544

URI:

https://boris.unibe.ch/id/eprint/169544

Actions (login required)

Edit item Edit item
Provide Feedback